The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Exenatide (Byetta) is a GLP-1-receptor agonist that recently was FDA-approved for treating type 2 diabetes. In an industry-sponsored randomized trial, 336 patients with suboptimally controlled ...

Although MG hasn’t revealed exact specifications yet, going by the dimensions of the international-spec D90 Max, the Majestor could measure 5,046mm in length, 2,016mm in width and 1,876mm in ...

MG showcased three new offerings, including an electric MPV, a flagship SUV and an SUV with a new powertrain option at the Auto Expo 2025 MG has gone all guns blazing at the Bharat Mobility Global ...

While the electric sportscar was revealed back in 2024, this is the first time it has been showcased in India. BHPian blackwasp recently shared this with other enthusiasts: Big shoutout to .anshuman ...

MG introduced the Majestor three-row SUV at the Bharat Mobility Expo in India. The new SUV is a basically rebadged Maxus/LDV D90. MG describes the Majestor as the “tallest, longest, and widest ...

STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo, all administered once weekly. The trial included 1,407 ...